6Suppliers
2Customers
1Debt Items
6Related Chains

Cumberland Pharmaceuticals Inc. Suppliers

TickerNameConfidenceEvidence
APOTEX-INC APOTEX-INC 92% Through the Transaction Apotex will create a U.S. branded pharmaceutical platform to build upon, by delivering specialty medicines that improve the quality of patient care.
1600-WEST-END-AVENUE-PARTNERS-LLC 1600-WEST-END-AVENUE-PARTNERS-LLC 90% On November 15, 2021, Cumberland entered into a lease (the "Broadwest Lease"), pursuant to which the Company leases approximately 16,903 rentable square feet of space (the "Leased Premise") at the Br…
KYOWA-KIRIN-INC KYOWA-KIRIN-INC 90% On January 3, 2022, Cumberland acquired the U.S. rights to the FDA-approved oncology-supportive care medicine Sancuso from Kyowa Kirin, Inc. ("Kyowa Kirin"), the U.S. affiliate of Japan-based Kyowa K…
NORDIC-B-V NORDIC-B-V 90% Effective June 30, 2023, the Company returned all rights of RediTrex back to Nordic B.V., and will receive a long-term royalty on any sales of the product in the future.
THERAVANCE THERAVANCE 80% The contingent consideration earned and accrued in operating expenses is paid to Theravance quarterly.
HRTX Heron Therapeutics, Inc. 72% Reciprocal relationship from HRTX graph: Reciprocal relationship from CPIX graph: Reciprocal relationship from HRTX graph: Reciprocal relationship from CPIX graph: Reciprocal relationship from HRTX g…

Cumberland Pharmaceuticals Inc. Customers

TickerNameConfidenceEvidence
CHINA-DISTRIBUTION-PARTNER CHINA-DISTRIBUTION-PARTNER 90% In early 2025, Cumberland received a $ 3.0 million milestone payment from our distribution partner in China associated with the approval of Vibativ for that market.
HRTX Heron Therapeutics, Inc. 72% Reciprocal relationship from HRTX graph: omer-based composition. Furthermore, our Biochronomer Technology is designed to permit more than one pharmacological agent to be incorporated, such that multi…

Cumberland Pharmaceuticals Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
CPIX-DEBT Debt stack $10.1M 90% Market cache reports total debt of $10.1M.

Cumberland Pharmaceuticals Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Cumberland Pharmaceuticals Inc..

Cumberland Pharmaceuticals Inc. Ownership

HolderNameConfidenceEvidence
CPIX-OWNER-VANGUARD-GROUP-INC Vanguard Group Inc 95% 13F/ownership overlay lists Vanguard Group Inc; shares held 411,786; ownership 2.75%; value $1.3M; as of 2025-12-31.
CPIX-OWNER-BRIDGEWAY-CAPITAL-MANAGEMENT-LLC Bridgeway Capital Management, LLC 95% 13F/ownership overlay lists Bridgeway Capital Management, LLC; shares held 163,468; ownership 1.09%; value $498,577; as of 2025-12-31.
CPIX-OWNER-PERCEPTIVE-ADVISORS-LLC Perceptive Advisors Llc 95% 13F/ownership overlay lists Perceptive Advisors Llc; shares held 341,087; ownership 2.28%; value $1.0M; as of 2025-12-31.
CPIX-OWNER-J-GOLDMAN-CO-L-P J. Goldman & Co., L.P. 95% 13F/ownership overlay lists J. Goldman & Co., L.P.; shares held 94,541; ownership 0.63%; value $288,350; as of 2025-12-31.
CPIX-OWNER-DIMENSIONAL-FUND-ADVISORS-LP Dimensional Fund Advisors LP 95% 13F/ownership overlay lists Dimensional Fund Advisors LP; shares held 272,278; ownership 1.82%; value $830,447; as of 2025-12-31.
CPIX-OWNER-GEODE-CAPITAL-MANAGEMENT-LLC Geode Capital Management, LLC 95% 13F/ownership overlay lists Geode Capital Management, LLC; shares held 107,274; ownership 0.72%; value $327,185; as of 2025-12-31.
CPIX-OWNER-BANK-OF-NEW-YORK-MELLON-CORPORATION Bank Of New York Mellon Corporation 95% 13F/ownership overlay lists Bank Of New York Mellon Corporation; shares held 72,513; ownership 0.48%; value $221,164; as of 2025-12-31.
CPIX-OWNER-IKARIAN-CAPITAL-LLC Ikarian Capital, LLC 95% 13F/ownership overlay lists Ikarian Capital, LLC; shares held 555,932; ownership 3.72%; value $1.7M; as of 2025-12-31.
CPIX-OWNER-RENAISSANCE-TECHNOLOGIES-LLC Renaissance Technologies, LLC 95% 13F/ownership overlay lists Renaissance Technologies, LLC; shares held 472,163; ownership 3.16%; value $1.4M; as of 2025-12-31.
CPIX-OWNER-BOOTHBAY-FUND-MANAGEMENT-LLC Boothbay Fund Management, LLC 95% 13F/ownership overlay lists Boothbay Fund Management, LLC; shares held 128,507; ownership 0.86%; value $391,946; as of 2025-12-31.

Cumberland Pharmaceuticals Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
HRTX Heron Therapeutics, Inc. 100.00 1 ['customer', 'supplier']
HTGC Hercules Capital, Inc. 50.00 2
ORANY ORANGE 50.00 2
TKPHF Takeda Pharmaceutical Company Limited 50.00 2
MRK Merck & Co., Inc. 50.00 2
PCRX Pacira BioSciences, Inc. 50.00 2